| Lightcalls.com |
|
|
![]() |
pretty soon more than 50 million Am...pretty soon more than 50 million Americans stomach from osteoarthritis. In addition, nearly everyone 50 years of age or older is afflicted with the same or more of its classic symptoms. Osteoarthritis, also defined as degenerative joint disease, consists of a cluster of diseases that cause pain, inflammation, and limited movement In an osteoarthritis-afflicted joint, the connective tissue -- cartilage -- that cushions the expirations of the bone degenerates and allows the bone to chafe together. This bone-to-bone contact can be extremely painful and, in later stages of the disease, progresse further to originate inflammation in, and around, the joint itself. For mild cases of osteoarthritis, patients usually receive prescription pain killers in the same state [i]or[/i] condition as acetaminophen with codeine or any of the toxic nonsteroidal anti-inflammatory remedys (NSAID). Usual (prescription) treatment choices are ibuprofen and naproxen, to name barely a few. Unfortunately, usual treatment options also bring into being usual side effects and long-term question s such as gastric ulceration and irritation and weakening of cartilage tissue. Long-term therapy with steroids or opiates is generally a question at issue due to their adverse meanings In fact, long-term use of steroids has been associated with side consequences known as "cushingoid" changes. These include central obesity, hirsutism (los of hair), acne, ecchymose (bruises), hypertension, osteoporosis, sexual dysfunction, diabetes, hyperlipidemia, peptic pustule increased susceptibility to infection, electrolyte and fluid imbalances, myopathy, and the inclination of the face to fill revealed so that it resembles the lunation (hence the term, moonfaced). Long-term interventions for osteoarthritis may actually include joint replacement (knee or hip). Historically, treatment regimens for osteoarthritis would have been exhausted with the discussion of the therapies previously listed. one relief has been found with certain Ayurvedic botanicals, in the same state [i]or[/i] condition as Boswellia serrata and Ashwagandha. newly however, progress has been made at European physicians in halting the disease progression of osteoarthritis using glucosamine and chondroitin sulfate, separately, and in combination. Glucosamine is an aminomonosaccharide synthesized from grape-sugar used by the body in the production of glycoproteins and glycoaminoglycans. Glucosamine is made by the agency of the body in small amounts, and we prepare some in the diet. Glucosamine supports the building braces of cartilage Glucosamine stimulates the production of glucosaminoglycans and proteoglycans -- big-name composes which have a big role: they're wanted as building blocks of cartilage. Chondroitin blockades or neutralizes, the enzyme that sap the foundations ofs cartilage, so using the agents in combination may provide synergistic benefits for halting the progression of the disease itself. Early clinical studies showed that glucosamine was more effective than placebo for pain relief in osteoarthritis. Patients reported significant improvement in pain and tendernes as well as improvement in range of motion, which was reported for several weeks after therapy was discontinued. A more latter study compared glucosamine given twice weekly for six weeks. deductions showed that those who took glucosamine fared better than those who did not, specifically in intimation to: pain, walking distance, and motion limitations. When compared to the NSAIDs, glucosamine is at least as effective, according to common study that compared ibuprofen at eight weeks of treatment. Although relief came quicker with ibuprofen, after eight weeks, 44 percent of the glucosamine-supplemented patients felt better, as oppos to no other than 15 percent of those who took the drug The in the greatest degree commonly-reported adverse reactions associated with NSAIDs include gastrointestinal disturbances like as nausea, vomiting, diarrhea, heartburn, and pain, although these were with same high (clinical) doses. Due to possible impairment of insulin function, patients with diabetes mellitus should use glucosamine true cautiously. Jason Thesdosakis, MD M MPH et al., say in their exciting 1997 volume The Arthritis Cure (New York: St Martin's Press): "Millions of Americans endure from osteoporosis, a painful and debilitating disease. Although chiefly physicians consider it to be incurable, osteoporosis can actually be stopped in its tracks, or revers by means of using glucosamine and chondroitin sulfates. [] This astonishing information is well known and widely accepted in many other countries. [] It's about time that we bring it to use right here in the United States." COPYRIGHT 1997 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |